Heritage first half year for IZB

Image caption: IZB.

The Innovation and Founder Center for Biotechnology (IZB) in Martinsried near Munich is looking forward to a first round of funding in the first half of 2024. “I am glad that there are no start-ups offering financing opportunities. Over 530 million euros and more than 90% of investments in German biotechnology went to an IZB fund. The great interest in life science investors and companies in IZB is focused on the high quality of research and development on an unreliable campus. Let more start-ups explore their clinical phase and explore their first careers,” said Christian Gnam, Managing Director of the Innovation and Founder Centers for Biotechnology.

Series B2 financing for Tubulis

I think Tubuli is a Series B2 financing at a height of 128 million. EUR, with the clinical entity of the company’s own ADC pipeline, which is a solid Tumore ausgerichtet, is described. The financing round of EQT Life Sciences and Nextech Invest has started. This means that the new US-Fond Frazier Life Sciences and Deep Track Capital are all the best investors in the run.

$4.5 million for Eisbach

Ebenfalls im Marz Eisbach Bio received 4.5 Mio. USD from the American Cancer Focus Fund with a phase 1/2 study with the investigated drug candidate EIS-12656. The Cancer Focus Fund presents as a special investment fund that makes financial resources and clinical treatments for the financing of credits possible. Eisbach’s clinical study and patients with refractory solid tumors will be carried out at the MD Anderson Cancer Center in Texas.

Insempra receives USD 20 million

In some cases, the purchase is made with a total amount of 20 million. USD Financing for the development of next-generation natural inhalants. Top investors EQT Ventures, BlueYard Capital, Possible Ventures, Taavet Sten and Acequia Capital are new investors in the run. If the financial sector focuses on the market orientation of the company, natural and internal nachholtige substances for the cosmetic and food industry are developed.

Bisher größte Runde für Biotech went and ITM

ITM Isotope Technologies, IZB-Mieter at Location Freising-Weihenstephan, started in June with 188 million. EUR the largest financing round in the German biotech industry in those years. The main investor is Temasek, like BlackRock, Qatar Investment Authority (QIA), ATHOS and Carbyne in the financing of the financing. The ITM will use the capital for the further development of its medicine pipeline benefits and the market introduction of its therapeutics ITM-11 for the treatment of tumors in the Verdaungstrakt-vorberien.

Large Series A Funding for SciRhom

At the beginning of the second half of 2024, SciRhom secured a €63 million Series A financing, with von Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital and Wellington Partners joining forces with new investors Bayern Kapital and top investors High-Tech Gründerfonds (HTGF) and PhiFund Ventures. SciRhom is expected to hold the middle ground, a clinical trial for its volatile lung program for its effectiveness. The first clinical study with SR-878, a highly specific monoclonal antibody against the disease iRhom2, is set to begin in the second half of 2024.

$150 million for CatalYm

In July, the Immuno-Company CatalYm secured a Series D financing round of EUR 150 million. With USD, a phase 2b incubation program for the visugromab program is being further expanded. The round of new investors Canaan Partners and Bioqube Ventures focused on Forbion’s Growth Opportunities Fund (“Forbion Growth”), Omega Funds and Gilde Healthcare. Top investors Jeito Capital, Brandon Capital Partners, Novartis Venture Fund and Vesalius Biocapital III are involved in the financing.

Closing at MorphoSys

No more financing where Halbjah a prominent IZB alumnus is bought. The MorphoSys AG in February a Vereinbarung zur Übernahme by the Pharmakonzern Novartis for a total of 2.7 billion euros. During the overarching phase, which is followed in most cases, Novartis starts the Oncology Pipeline.

Life Science Pitch Day with more than 40 investors

A new biotech start-up with Life Science investors is busy with the end of July of the next Life Science Pitch Day in Zusammenarbeit with the High-Tech Gründerfonds (HTGF), Bayer, Boehringer Ingelheim and MEDICE in IZB-statt. There are many new start-ups that can make new investments through medical problems – from bacterial infections to their current investments – for more than 40 investors. I started with Dr. Daniel Vitt, CEO of the IZB alumnus Immunic Therapeutics, a Keynote speech on the path of a biotech company to a successful IPO. This is a rich location for the start-ups, with network contacts in the venture capital firm that they need.

Fresh wind on campus

In April 2024, Christian Gnam, as Geschäftsführer des Innovations- und Gründerzentrums Biotechnologie (IZB), treated the Nachfolge von Dr. Peter Hanns Zobel an. Erfahrene Manager, of a large international network founded as Geschäftsführer at InsurTech Hub Munich (ITHM), a global innovation platform for the Versicherungswirtschaft, is that. In this function, most of the hubs are available, the cooperation between start-ups, tech firms and diversifications and the ITHM continuous strategic development.

Two new members on board

In addition, the IZB welcomed two new start-ups in the first half year. Smey has developed an innovation in the life cycle of life and sets core ingredients for hair, health, life, security and sustainability of livelihood and cosmetic products. The start-ups are low-free protein, fermentative and it is a new generation of sustenance products. Oncobeta specializes in an innovative therapy for non-melanotic scalp cancers, with the eye, the treatment by the non-invasive Rhenium-SCT® therapy of the third-line treatment. The start-up has developed a medical device and instrumentation, which offers a unique experience for the effective duration of the therapy.

MAxL am at the beginning

At the end of June, the “Munich Accelerator Life Sciences & Medicine” (MAxL) will be active on the IZB Campus. MAxL has helped pre-seed and start-up teams from Bavaria and Darüber with an exclusive high-end infrastructure, with many supported work, co-working and community spaces, a structural incubation and coaching program as well as valuable networking opportunities. The project is being implemented by the Bavarian State Ministry for Economic Affairs, Regional Development and Energy with 8.5 million euros funded and guided by the Cluster Management Company BioM.

Fortschritte in Wissenschaft und Klinik

I started the thermosome study in February in a phase 1 study with the Wirkstoff candidates THE001. It is an interventional phase 1 dose escalation study in patients with local fortgeschrittenem, inoperable or metastatic disease undergoing two German clinical treatments. If the Data Safety Monitoring Board does not hang up, the first dose of this study is a problem.

Tubuli is presented at the new preclinical data for the leading ADC candidates that form a solid tumor in the years of the American Association for Cancer Research (AACR) in San Diego. The current generation poster presentations are based on the ADC candidates TUB-030 and TUB-040, the quality of both of the next generation Tubutecan ADCs is determined by developing models with lower target expression and repeated responses. In June, the first patient was treated in a Phase 1/2a study in patients with platinum resistance tests (PROC) or rezidiviertem/refractärem non-kleinzellige lung studies (NSCLC) with TUB-040. For these ADC candidates, Tubuli has achieved Fast Track status from the FDA.

In June, SciRhom started generating an Antrags on the Clinical Test by the Sterreichische Zulassungsbehörde (BASG/AGES) for the Development Program SR-878. The study is a new type of study, in which the antibody of autoimmune diseases is treated, while the certainty that volunteers will be treated and in a second part of the study will start the study in a pleasant way.